Table 1.

Prevalence of iciHHV-6 status according to sex and cancer prevalence from CARTaGENE

Sexn (%)iciHHV-6N (%)iciHHV-6+N (%; 95% CI)
Males9,560 (48.78)9,496 (48.74)64 (0.33; 0.47–0.67)
Females10,037 (51.22)9,988 (51.26)49 (0.25; 0.34–0.53)
Total19,597 (100)19,484 (99.42)113 (0.58)
Cancer typeiciHHV-6N = 19,484 (%)iciHHV-6+N = 113 (%)PaiciHHV-6 males n = 9,496 (%)iciHHV-6+ males n = 64 (%)PaiciHHV-6 females n = 9,988 (%)iciHHV-6+ females n = 49 (%)PaOR (95% CI)
Cancer (all)1,553 (7.97)12 (10.62)0.38621 (6.54)5 (7.81)0.86932 (9.33)7 (14.29)0.341.63 (0.73–3.62)
Breast326 (1.67)4 (3.54)0.243 (0.03)0 (0.00)ND323 (3.23)4 (8.16)0.122.66 (0.95–7.44)
Skin327 (1.68)0 (0.00)0.31152 (1.60)0 (0.00)0.60175 (1.75)0 (0.00)0.700.56 (0.03–9.20)
Prostate177 (0.91)1 (0.88)0.64177 (1.86)1 (1.56)0.84N/AN/AN/AN/A
Cervix124 (0.64)0 (0.00)0.80N/AN/AN/A124 (1.24)0 (0.00)0.800.80 (0.04–13.06)
  • Abbreviations: N/A, not applicable; ND, not determined (too few cases).

  • aFisher exact test.